Shares of Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) have been given a consensus rating of "Buy" by the seven analysts that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.00.
NKTX has been the topic of several recent research reports. RODMAN&RENSHAW upgraded Nkarta to a "strong-buy" rating in a report on Wednesday, October 9th. Needham & Company LLC decreased their price target on Nkarta from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Friday, November 8th. Mizuho decreased their price target on Nkarta from $20.00 to $16.00 and set an "outperform" rating on the stock in a report on Thursday, November 21st. Rodman & Renshaw initiated coverage on Nkarta in a report on Wednesday, October 9th. They set a "buy" rating and a $14.00 target price on the stock. Finally, HC Wainwright reduced their target price on Nkarta from $22.00 to $18.00 and set a "buy" rating on the stock in a report on Monday, November 11th.
Check Out Our Latest Research Report on Nkarta
Nkarta Trading Down 0.8 %
Nkarta stock traded down $0.02 during mid-day trading on Friday, hitting $2.47. The stock had a trading volume of 1,770,357 shares, compared to its average volume of 1,352,777. The stock has a 50-day simple moving average of $2.54 and a two-hundred day simple moving average of $4.21. The stock has a market capitalization of $174.31 million, a PE ratio of -1.31 and a beta of 0.85. Nkarta has a 12 month low of $2.08 and a 12 month high of $16.24.
Institutional Investors Weigh In On Nkarta
A number of hedge funds have recently modified their holdings of NKTX. Erste Asset Management GmbH acquired a new stake in shares of Nkarta during the third quarter worth about $33,000. GAMMA Investing LLC raised its position in shares of Nkarta by 110.9% during the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company's stock worth $45,000 after purchasing an additional 5,243 shares during the period. Forefront Analytics LLC acquired a new stake in shares of Nkarta during the second quarter worth about $70,000. Intech Investment Management LLC acquired a new stake in shares of Nkarta during the third quarter worth about $74,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Nkarta during the third quarter worth about $93,000. Institutional investors and hedge funds own 80.54% of the company's stock.
About Nkarta
(
Get Free ReportNkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Further Reading
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
